Creating RNA nanoparticles to enhance gene expression in solid tumors
Official title: Development and characterization of self-amplifying RNA Lipid Nanoparticles for potent and multiplex gene expression in solid tumors
Funded at Boston University (Charles River Campus) · NIH-10998606 · Data updated 2026-11-12
This study is testing a new way to deliver gene therapy directly to solid tumors to make cancer treatments like chemotherapy and immunotherapy work better, so patients might have a more effective and personalized option for fighting their cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $40,671 |
| NIH project number | 1F31CA295073-01 |
| Project ID | NIH-10998606 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with solid tumors who are seeking innovative treatment options.
✕Less likely to help
Patients with non-solid tumors or those who are not eligible for gene therapy may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver gene therapy directly to solid tumors, which are a major challenge in cancer treatment. The approach uses self-amplifying RNA combined with lipid nanoparticles to provide a sustained and effective delivery of multiple therapeutic agents. By targeting the tumor directly, this method aims to improve the effectiveness of existing treatments like chemotherapy and immunotherapy. Patients may benefit from a more potent and tailored treatment option that could enhance tumor clearance.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for solid tumors, potentially improving patient outcomes.
How similar studies have gone: Previous research has shown promise with similar gene delivery methods, indicating potential for success in this novel approach.
Where this research is happening
-
Boston University (Charles River Campus)
Boston, United States Active
Researchers
- Principal investigator: Nambiar, Arun Kannoth — Boston University (Charles River Campus)
- Study coordinator: Nambiar, Arun Kannoth
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.